SG Americas Securities LLC Decreases Stock Position in Incyte Corporation $INCY

14 Jan 2026, 11:04 by Michael Walen · The Markets Daily

SG Americas Securities LLC trimmed its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 97.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 25,666 shares of the biopharmaceutical company’s stock after selling 923,508 shares during the period. SG Americas Securities LLC’s holdings in Incyte were worth $2,177,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in INCY. Arrowstreet Capital Limited Partnership increased its stake in shares of Incyte by 701.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,730,648 shares of the biopharmaceutical company’s stock worth $185,957,000 after purchasing an additional 2,390,084 shares in the last quarter. AQR Capital Management LLC increased its position in Incyte by 21.8% during the second quarter. AQR Capital Management LLC now owns 8,201,455 shares of the biopharmaceutical company’s stock worth $558,519,000 after buying an additional 1,465,286 shares in the last quarter. Norges Bank acquired a new position in shares of Incyte in the second quarter worth $96,776,000. Pacer Advisors Inc. lifted its position in shares of Incyte by 8,091.6% in the third quarter. Pacer Advisors Inc. now owns 1,248,642 shares of the biopharmaceutical company’s stock valued at $105,897,000 after acquiring an additional 1,233,399 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Incyte during the second quarter valued at $82,485,000. Institutional investors and hedge funds own 96.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on INCY shares. Barclays raised their price target on shares of Incyte from $101.00 to $115.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. Oppenheimer cut shares of Incyte from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. Zacks Research lowered Incyte from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $90.00 price objective on shares of Incyte in a research report on Thursday, January 8th. Finally, Piper Sandler increased their target price on Incyte from $82.00 to $102.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Ten research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Incyte has a consensus rating of “Hold” and an average price target of $101.31.

Read Our Latest Report on INCY

Incyte News Roundup

Here are the key news stories impacting Incyte this week:

Positive Sentiment: TD Cowen raised its price target from $101 to $128 and reiterated a Buy rating, implying meaningful upside and signaling confidence in Incyte’s pipeline and growth outlook. This upgrade likely supported buying interest earlier in the session. Benzinga
Positive Sentiment: CEO Bill Meury emphasized that blood-cancer therapy development is central to Incyte’s identity and discussed potential M&A and product-pipeline execution on CNBC’s Fast Money — comments that investors typically view as constructive for longer-term revenue diversification and deal-led growth. Incyte CEO Bill Meury interview
Neutral Sentiment: Pre-earnings commentary (Zacks, Barchart previews) highlights Incyte’s history of earnings beats and analysts projecting a double-digit surge in Q4 EPS — this raises expectations ahead of the report and increases the risk/reward around the release. Zacks beat article Barchart preview
Neutral Sentiment: Incyte’s presentation at the J.P. Morgan Healthcare Conference and the published transcript keep the company in investors’ view — helpful for visibility but not an immediate catalyst unless new guidance or data were disclosed. J.P. Morgan transcript
Neutral Sentiment: Marketing/brand activity (Winnie Harlow vitiligo campaign) may support commercial awareness for non-oncology assets but is unlikely to move the stock materially on its own. MMM Online
Neutral Sentiment: Some analyst shops (Morgan Stanley) remain neutral/hold, reflecting balanced views that the stock has near-term strength but uncertainty beyond Jakafi — this maintains mixed pressure on the shares. TipRanks hold note
Negative Sentiment: BMO Capital’s Evan Seigerman maintained a Sell rating and $75 price target, calling out a post-Jakafi revenue gap and execution risks — that contrasting negative view likely pressured the stock as investors weighed who’s right on long-term revenue sustainability. TipRanks BMO sell note

Insider Buying and Selling

In other news, EVP Mohamed Khairie Issa sold 10,856 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total value of $1,184,063.92. Following the transaction, the executive vice president owned 66,132 shares of the company’s stock, valued at approximately $7,213,017.24. This trade represents a 14.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael James Morrissey sold 4,323 shares of the company’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $97.26, for a total transaction of $420,454.98. Following the sale, the executive vice president directly owned 27,507 shares of the company’s stock, valued at approximately $2,675,330.82. This trade represents a 13.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 98,897 shares of company stock valued at $9,869,376. 17.80% of the stock is owned by corporate insiders.

Incyte Trading Down 2.7%

Shares of INCY opened at $103.43 on Wednesday. Incyte Corporation has a twelve month low of $53.56 and a twelve month high of $112.29. The firm has a market capitalization of $20.31 billion, a P/E ratio of 17.32, a price-to-earnings-growth ratio of 0.64 and a beta of 0.82. The company has a current ratio of 3.20, a quick ratio of 3.13 and a debt-to-equity ratio of 0.01. The stock’s fifty day simple moving average is $102.21 and its 200 day simple moving average is $88.87.

Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $2.26 EPS for the quarter, topping the consensus estimate of $1.65 by $0.61. Incyte had a return on equity of 26.56% and a net margin of 24.69%.The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.26 billion. During the same period in the prior year, the firm posted $1.07 earnings per share. The firm’s revenue was up 20.0% on a year-over-year basis. On average, equities research analysts forecast that Incyte Corporation will post 4.86 earnings per share for the current year.

About Incyte

(Free Report)

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.